Free Trial Information
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...newco creation, based on number of companies, but only attracted a single pharma spinout -- Izana Bioscience...
Read More
BioCentury | Dec 15, 2017
Company News

Takeda grants newco Izana rights to autoimmune candidate

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) granted newco Izana Bioscience (London, UK) exclusive, worldwide rights to develop and...
...half, Izana plans to begin a Phase II trial of namilumab to treat ankylosing spondylitis. Izana...
...Oaks, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Izana Bioscience, London, UK Business: Autoimmune Alicia Parker IZN-101 MT203 namilumab Amgen Inc. Izana Bioscience Takeda...
Read More
Items per page:
1 - 2 of 2
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...newco creation, based on number of companies, but only attracted a single pharma spinout -- Izana Bioscience...
Read More
BioCentury | Dec 15, 2017
Company News

Takeda grants newco Izana rights to autoimmune candidate

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) granted newco Izana Bioscience (London, UK) exclusive, worldwide rights to develop and...
...half, Izana plans to begin a Phase II trial of namilumab to treat ankylosing spondylitis. Izana...
...Oaks, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Izana Bioscience, London, UK Business: Autoimmune Alicia Parker IZN-101 MT203 namilumab Amgen Inc. Izana Bioscience Takeda...
Read More
Items per page:
1 - 2 of 2